Synergistic association of sodium-glucose cotransporter-2 inhibitor and metformin on liver and non-liver complications in patients with type 2 diabetes mellitus and metabolic dysfunction-associated steatotic liver disease
In a nationwide cohort, SGLT-2i users were associated with a substantially lower risk of liver and non-liver complications than oGLD users among patients with diabetic MASLD. The risk was further reduced with concomitant metformin use.
Authors
- Rongtao Lai (ORCID: https://orcid.org/0000-0003-1704-7086)
- Ramsey Cheung (ORCID: https://orcid.org/0000-0002-0211-7013)
- Leslie Y. Kam (ORCID: https://orcid.org/0000-0002-0469-4543)
- Mindie H. Nguyen (ORCID: https://orcid.org/0000-0002-6275-4989)
- Ka Shing Cheung (ORCID: https://orcid.org/0000-0002-4838-378X)
- Man‐Fung Yuen (ORCID: https://orcid.org/0000-0001-7985-7725)
- Nicholas Chien
- Xianhua Mao (ORCID: https://orcid.org/0000-0003-4050-4759)
- Xinrong Zhang (ORCID: https://orcid.org/0000-0002-8393-8904)
- Wai‐Kay Seto (ORCID: https://orcid.org/0000-0002-9012-313X)
Institutions
- Shanghai Jiao Tong University (CN)
- VA Palo Alto Health Care System (US)
- Stanford Medicine (US)
- University of Hong Kong - Shenzhen Hospital (CN)
- University of Hong Kong (HK)
- Stanford University (US)
Publication Details
- Journal
- Gut
- Published
- 2024-08-08
- DOI
- https://doi.org/10.1136/gutjnl-2024-332481
- Citations
- 26
- Primary Topic
- Liver Disease Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 10.05